- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.11. | Entrada Therapeutics-Aktie erreicht 52-Wochen-Hoch bei 18,22 US-Dollar | 1 | Investing.com Deutsch | ||
| 05.11. | Entrada Therapeutics, Inc.: Entrada Therapeutics Reports Third Quarter 2024 Financial Results | 59 | GlobeNewswire (Europe) | - Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for DMD at 2024 World Muscle Society Annual Congress - - On track to submit... ► Artikel lesen | |
| 05.11. | Entrada Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | Entrada Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.10. | Entrada Therapeutics, Inc. (NASDAQ:TRDA) Insider Natarajan Sethuraman Sells 600 Shares | 2 | MarketBeat | ||
| 09.10. | Entrada Therapeutics Presents Data Supporting Advancement Of Duchenne Franchise | 3 | RTTNews | ||
| 09.10. | Entrada Therapeutics advances Duchenne treatment trials | 2 | Investing.com | ||
| ENTRADA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.10. | Entrada Therapeutics macht Fortschritte bei Duchenne-Behandlungsstudien | 3 | Investing.com Deutsch | ||
| 09.10. | Entrada Therapeutics, Inc.: Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society | 1 | GlobeNewswire (USA) | ||
| 24.09. | Entrada Therapeutics ernennt neuen Präsidenten für Forschung und Entwicklung | 2 | Investing.com Deutsch | ||
| 24.09. | Entrada Therapeutics appoints new President of R&D | 1 | Investing.com | ||
| 24.09. | Entrada Therapeutics, Inc.: Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development | 1 | GlobeNewswire (USA) | ||
| 10.09. | Entrada Therapeutics CFO sells shares worth over $47,000 | 1 | Investing.com | ||
| 06.09. | Entrada Therapeutics, Inc.: Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program | 87 | GlobeNewswire (Europe) | - Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne - - Announced in celebration... ► Artikel lesen | |
| 20.08. | Entrada Therapeutics exec sells over $440k in company stock | 1 | Investing.com | ||
| 14.08. | Entrada Therapeutics stock retains buy rating on strong Q2 net income | 1 | Investing.com | ||
| 13.08. | Entrada Therapeutics GAAP EPS of $1.55, revenue of $94.7M | 1 | Seeking Alpha | ||
| 13.08. | Entrada Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.08. | Entrada Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.06. | Entrada Therapeutics announces $100M registered direct offering | 1 | Seeking Alpha |
Seite:
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,361 | -2,43 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,350 | +4,96 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| RECURSION PHARMACEUTICALS | 5,780 | -4,30 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,040 | -1,80 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| ONCOLYTICS BIOTECH | 0,945 | 0,00 % | Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2024 Earnings Call Transcript | ||
| ARCTURUS THERAPEUTICS | 17,160 | +5,99 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,950 | 0,00 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
| SIGA TECHNOLOGIES | 6,265 | +0,24 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,280 | -0,42 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| VIR BIOTECHNOLOGY | 6,855 | +1,71 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,600 | +1,10 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 17,000 | 0,00 % | Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level | ||
| ARVINAS | 24,850 | +9,52 % | Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode | ||
| BIO-PATH | 0,790 | 0,00 % | Bio-Path Holdings, Inc.: Bio-Path Holdings Reports Third Quarter 2024 Financial Results | Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology... ► Artikel lesen |
Das Unternehmen ENTRADA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 18,080 Euro und damit +1,69 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENTRADA THERAPEUTICS INC finden Sie auf Wallstreet Online.
